“OnabotulinumtoxinA for Treatment of Moderate-to-Severe Horizontal Lines and Glabellar Lines from the Subject’s Perspective: Patient-Reported Satisfaction and Impact Outcomes from a Phase 3 Double-Blind Study” (2017) SKIN The Journal of Cutaneous Medicine, 1(3.1), p. s82. doi:10.25251/skin.1.supp.81.